ArticleJournal of visualized experiments : JoVE2026
Purification of HLA-G+ Extravillous Trophoblasts from Human Term Placental Tissues for Phenotyping and Functional Analysis.
Article in Journal of visualized experiments : JoVE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The human maternal-fetal interface represents a unique immunological environment where maternal immune cells and fetal extravilllous trophoblasts (EVT) engage in direct cellular contact to establish and maintain immune tolerance. EVT exhibit a distinct immunophenotype characterized by the expression of tolerogenic molecules, including HLA-G, PD-L1, and PD-L2, which play pivotal roles in modulating maternal immune responses. In addition, human EVT express HLA-C that can be directly recognized by maternal NK and T cells and promotes their activation. Importantly, no orthologues of HLA-C or HLA-G are present in animal models used for research, and murine trophoblast lack MHC expression. Thus, investigating the phenotypic and functional properties of human EVT from placental tissues, under both physiological and pathological conditions, is essential for elucidating the mechanisms underlying pregnancy maintenance and pathophysiology of placental inflammation associated with preeclampsia, preterm birth, fetal growth restriction, and placenta accreta. This protocol outlines a comprehensive methodology for the isolation and characterization of primary human EVT from healthy term placental tissue as well as after preterm birth and preeclampsia. It includes: (1) dissection of placental and chorionic membrane tissues; (2) enzymatic digestion and the preparation of single cell suspensions; (3) EVT purification by FACS sort; (4) Phenotypic characterization by high-dimensional flow cytometry; and (5) short-term in vitro culture and co-culture with maternal immune cells for up to 96 h. Emphasis is placed on obtaining highly pure and viable EVT suitable for downstream applications such as immunological functional assays, protein and gene expression analysis. The implementation of this protocol enables a robust and reproducible platform for advancing understanding of EVT and maternal immune cell interactions and its implications in both healthy and complicated pregnancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.